CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.2900
+0.0100 (3.57%)
Apr 9, 2026, 3:56 PM EST
CytoDyn Employees
CytoDyn had 13 employees as of May 31, 2025. The number of employees increased by 4 or 44.44% compared to the previous year.
Employees
13
Change (1Y)
4
Growth (1Y)
44.44%
Revenue / Employee
n/a
Profits / Employee
-$3,098,154
Market Cap
372.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| May 31, 2025 | 13 | 4 | 44.44% |
| May 31, 2024 | 9 | -3 | -25.00% |
| May 31, 2023 | 12 | -11 | -47.83% |
| May 31, 2022 | 23 | -1 | -4.17% |
| May 31, 2021 | 24 | 5 | 26.32% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 88 |
| Vaxart | 65 |
| Northwest Biotherapeutics | 25 |
| Nuo Therapeutics | 9 |
| Harvard Apparatus Regenerative Technology | 8 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
CytoDyn News
- 17 days ago - CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer - GlobeNewsWire
- 5 weeks ago - CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab - GlobeNewsWire
- 7 weeks ago - CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference - GlobeNewsWire
- 2 months ago - CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer - GlobeNewsWire
- 4 months ago - December 2025 Letter to Shareholders - GlobeNewsWire
- 4 months ago - CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 4 months ago - CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium - GlobeNewsWire
- 5 months ago - CytoDyn Secures $30 Million Commitment from Yorkville Advisors - GlobeNewsWire